Dyne Therapeutics, Inc. (DYN) Stock Competitors & Peer Comparison
See (DYN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DYN | $17.24 | -7.46% | 2.9B | -5.47 | -$3.15 | N/A |
| NVO | $42.92 | -2.61% | 190.7B | 10.08 | $4.26 | +4.19% |
| VRTX | $425.09 | -3.04% | 107.9B | 25.20 | $16.87 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $602.92 | +0.38% | 62.1B | 14.73 | $40.94 | +0.60% |
| ARGX | $802.17 | -4.06% | 49.6B | 35.67 | $22.49 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $286.12 | -3.22% | 38.2B | 71.71 | $3.99 | N/A |
| RVMD | $151.31 | -7.56% | 32.2B | -21.31 | -$7.10 | N/A |
| RPRX | $54.01 | -2.12% | 23.2B | 28.43 | $1.90 | +1.68% |
Stock Comparison
DYN vs NVO Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, NVO has a market cap of 190.7B. Regarding current trading prices, DYN is priced at $17.24, while NVO trades at $42.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas NVO's P/E ratio is 10.08. In terms of profitability, DYN's ROE is -0.58%, compared to NVO's ROE of +0.66%. Regarding short-term risk, DYN is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check NVO's competition here
DYN vs VRTX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, VRTX has a market cap of 107.9B. Regarding current trading prices, DYN is priced at $17.24, while VRTX trades at $425.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas VRTX's P/E ratio is 25.20. In terms of profitability, DYN's ROE is -0.58%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, DYN is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check VRTX's competition here
DYN vs VRNA Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, DYN is priced at $17.24, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas VRNA's P/E ratio is -102.80. In terms of profitability, DYN's ROE is -0.58%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, DYN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check VRNA's competition here
DYN vs REGN Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, REGN has a market cap of 62.1B. Regarding current trading prices, DYN is priced at $17.24, while REGN trades at $602.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas REGN's P/E ratio is 14.73. In terms of profitability, DYN's ROE is -0.58%, compared to REGN's ROE of +0.14%. Regarding short-term risk, DYN is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check REGN's competition here
DYN vs ARGX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ARGX has a market cap of 49.6B. Regarding current trading prices, DYN is priced at $17.24, while ARGX trades at $802.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ARGX's P/E ratio is 35.67. In terms of profitability, DYN's ROE is -0.58%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, DYN is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ARGX's competition here
DYN vs SGEN Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DYN is priced at $17.24, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DYN's ROE is -0.58%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DYN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check SGEN's competition here
DYN vs ALNY Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ALNY has a market cap of 38.2B. Regarding current trading prices, DYN is priced at $17.24, while ALNY trades at $286.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ALNY's P/E ratio is 71.71. In terms of profitability, DYN's ROE is -0.58%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, DYN is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ALNY's competition here
DYN vs RVMD Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, RVMD has a market cap of 32.2B. Regarding current trading prices, DYN is priced at $17.24, while RVMD trades at $151.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas RVMD's P/E ratio is -21.31. In terms of profitability, DYN's ROE is -0.58%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, DYN is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RVMD's competition here
DYN vs RPRX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, RPRX has a market cap of 23.2B. Regarding current trading prices, DYN is priced at $17.24, while RPRX trades at $54.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas RPRX's P/E ratio is 28.43. In terms of profitability, DYN's ROE is -0.58%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, DYN is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RPRX's competition here
DYN vs UTHR Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, UTHR has a market cap of 22.9B. Regarding current trading prices, DYN is priced at $17.24, while UTHR trades at $540.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas UTHR's P/E ratio is 19.96. In terms of profitability, DYN's ROE is -0.58%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, DYN is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check UTHR's competition here
DYN vs BNTX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, BNTX has a market cap of 22.5B. Regarding current trading prices, DYN is priced at $17.24, while BNTX trades at $89.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas BNTX's P/E ratio is -15.13. In terms of profitability, DYN's ROE is -0.58%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, DYN is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BNTX's competition here
DYN vs INSM Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, INSM has a market cap of 22.5B. Regarding current trading prices, DYN is priced at $17.24, while INSM trades at $103.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas INSM's P/E ratio is -18.01. In terms of profitability, DYN's ROE is -0.58%, compared to INSM's ROE of -1.30%. Regarding short-term risk, DYN is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check INSM's competition here
DYN vs ROIV Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ROIV has a market cap of 20.3B. Regarding current trading prices, DYN is priced at $17.24, while ROIV trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ROIV's P/E ratio is -52.31. In terms of profitability, DYN's ROE is -0.58%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, DYN is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ROIV's competition here
DYN vs BGNE Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DYN is priced at $17.24, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DYN's ROE is -0.58%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, DYN is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BGNE's competition here
DYN vs DNA-WT Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, DYN is priced at $17.24, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, DYN's ROE is -0.58%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, DYN is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check DNA-WT's competition here
DYN vs INCY Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, INCY has a market cap of 18.4B. Regarding current trading prices, DYN is priced at $17.24, while INCY trades at $92.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas INCY's P/E ratio is 13.03. In terms of profitability, DYN's ROE is -0.58%, compared to INCY's ROE of +0.29%. Regarding short-term risk, DYN is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check INCY's competition here
DYN vs MRNA Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, MRNA has a market cap of 18.1B. Regarding current trading prices, DYN is priced at $17.24, while MRNA trades at $45.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas MRNA's P/E ratio is -5.61. In terms of profitability, DYN's ROE is -0.58%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, DYN is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MRNA's competition here
DYN vs NBIX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, NBIX has a market cap of 15.6B. Regarding current trading prices, DYN is priced at $17.24, while NBIX trades at $154.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas NBIX's P/E ratio is 23.78. In terms of profitability, DYN's ROE is -0.58%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, DYN is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check NBIX's competition here
DYN vs GMAB Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, GMAB has a market cap of 14.6B. Regarding current trading prices, DYN is priced at $17.24, while GMAB trades at $23.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas GMAB's P/E ratio is 18.21. In terms of profitability, DYN's ROE is -0.58%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, DYN is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check GMAB's competition here
DYN vs JAZZ Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, JAZZ has a market cap of 14.2B. Regarding current trading prices, DYN is priced at $17.24, while JAZZ trades at $226.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas JAZZ's P/E ratio is 1884.33. In terms of profitability, DYN's ROE is -0.58%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, DYN is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check JAZZ's competition here
DYN vs ASND Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ASND has a market cap of 13.4B. Regarding current trading prices, DYN is priced at $17.24, while ASND trades at $216.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ASND's P/E ratio is 24.60. In terms of profitability, DYN's ROE is -0.58%, compared to ASND's ROE of -56.42%. Regarding short-term risk, DYN is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ASND's competition here
DYN vs KRTX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DYN is priced at $17.24, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DYN's ROE is -0.58%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DYN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check KRTX's competition here
DYN vs BBIO Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, BBIO has a market cap of 12.5B. Regarding current trading prices, DYN is priced at $17.24, while BBIO trades at $63.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas BBIO's P/E ratio is -17.07. In terms of profitability, DYN's ROE is -0.58%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, DYN is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BBIO's competition here
DYN vs EXEL Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, EXEL has a market cap of 12.2B. Regarding current trading prices, DYN is priced at $17.24, while EXEL trades at $48.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas EXEL's P/E ratio is 16.07. In terms of profitability, DYN's ROE is -0.58%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, DYN is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check EXEL's competition here
DYN vs IONS Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, IONS has a market cap of 12.1B. Regarding current trading prices, DYN is priced at $17.24, while IONS trades at $72.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas IONS's P/E ratio is -36.30. In terms of profitability, DYN's ROE is -0.58%, compared to IONS's ROE of -0.59%. Regarding short-term risk, DYN is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check IONS's competition here
DYN vs SMMT Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, SMMT has a market cap of 11.5B. Regarding current trading prices, DYN is priced at $17.24, while SMMT trades at $14.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas SMMT's P/E ratio is -9.35. In terms of profitability, DYN's ROE is -0.58%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, DYN is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check SMMT's competition here
DYN vs AXSM Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, AXSM has a market cap of 11.4B. Regarding current trading prices, DYN is priced at $17.24, while AXSM trades at $222.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas AXSM's P/E ratio is -59.91. In terms of profitability, DYN's ROE is -0.58%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, DYN is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check AXSM's competition here
DYN vs RNAM Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, DYN is priced at $17.24, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas RNAM's P/E ratio is -17.39. In terms of profitability, DYN's ROE is -0.58%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, DYN is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RNAM's competition here
DYN vs MDGL Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, MDGL has a market cap of 10.4B. Regarding current trading prices, DYN is priced at $17.24, while MDGL trades at $452.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas MDGL's P/E ratio is -33.59. In terms of profitability, DYN's ROE is -0.58%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, DYN is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MDGL's competition here
DYN vs BMRN Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, BMRN has a market cap of 10.3B. Regarding current trading prices, DYN is priced at $17.24, while BMRN trades at $53.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas BMRN's P/E ratio is 38.36. In terms of profitability, DYN's ROE is -0.58%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, DYN is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BMRN's competition here
DYN vs ARWR Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ARWR has a market cap of 10B. Regarding current trading prices, DYN is priced at $17.24, while ARWR trades at $70.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ARWR's P/E ratio is -31.20. In terms of profitability, DYN's ROE is -0.58%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, DYN is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ARWR's competition here
DYN vs RXDX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DYN is priced at $17.24, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DYN's ROE is -0.58%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DYN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RXDX's competition here
DYN vs CYTK Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CYTK has a market cap of 8.8B. Regarding current trading prices, DYN is priced at $17.24, while CYTK trades at $70.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CYTK's P/E ratio is -10.35. In terms of profitability, DYN's ROE is -0.58%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, DYN is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CYTK's competition here
DYN vs IMGN Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DYN is priced at $17.24, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DYN's ROE is -0.58%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, DYN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check IMGN's competition here
DYN vs KRYS Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, KRYS has a market cap of 8.6B. Regarding current trading prices, DYN is priced at $17.24, while KRYS trades at $293.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas KRYS's P/E ratio is 39.30. In terms of profitability, DYN's ROE is -0.58%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, DYN is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check KRYS's competition here
DYN vs BPMC Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DYN is priced at $17.24, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas BPMC's P/E ratio is -51.58. In terms of profitability, DYN's ROE is -0.58%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, DYN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check BPMC's competition here
DYN vs CERE Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DYN is priced at $17.24, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CERE's P/E ratio is -16.47. In terms of profitability, DYN's ROE is -0.58%, compared to CERE's ROE of -0.72%. Regarding short-term risk, DYN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CERE's competition here
DYN vs HALO Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, DYN is priced at $17.24, while HALO trades at $66.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas HALO's P/E ratio is 23.26. In terms of profitability, DYN's ROE is -0.58%, compared to HALO's ROE of +1.26%. Regarding short-term risk, DYN is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check HALO's competition here
DYN vs TECH Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, TECH has a market cap of 7.8B. Regarding current trading prices, DYN is priced at $17.24, while TECH trades at $49.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas TECH's P/E ratio is 71.10. In terms of profitability, DYN's ROE is -0.58%, compared to TECH's ROE of +0.05%. Regarding short-term risk, DYN is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TECH's competition here
DYN vs CORT Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, DYN is priced at $17.24, while CORT trades at $71.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CORT's P/E ratio is 203.47. In terms of profitability, DYN's ROE is -0.58%, compared to CORT's ROE of +0.08%. Regarding short-term risk, DYN is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CORT's competition here
DYN vs IBRX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, IBRX has a market cap of 7.6B. Regarding current trading prices, DYN is priced at $17.24, while IBRX trades at $7.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas IBRX's P/E ratio is -8.51. In terms of profitability, DYN's ROE is -0.58%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, DYN is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check IBRX's competition here
DYN vs MTSR Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, DYN is priced at $17.24, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas MTSR's P/E ratio is -23.58. In terms of profitability, DYN's ROE is -0.58%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, DYN is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MTSR's competition here
DYN vs ALKS Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ALKS has a market cap of 6.9B. Regarding current trading prices, DYN is priced at $17.24, while ALKS trades at $41.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ALKS's P/E ratio is 45.91. In terms of profitability, DYN's ROE is -0.58%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, DYN is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ALKS's competition here
DYN vs PCVX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, PCVX has a market cap of 6.8B. Regarding current trading prices, DYN is priced at $17.24, while PCVX trades at $47.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas PCVX's P/E ratio is -6.88. In terms of profitability, DYN's ROE is -0.58%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, DYN is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check PCVX's competition here
DYN vs MRUS Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, DYN is priced at $17.24, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas MRUS's P/E ratio is -17.05. In terms of profitability, DYN's ROE is -0.58%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, DYN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MRUS's competition here
DYN vs ACLX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, DYN is priced at $17.24, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ACLX's P/E ratio is -28.27. In terms of profitability, DYN's ROE is -0.58%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, DYN is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ACLX's competition here
DYN vs NUVL Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, NUVL has a market cap of 6.7B. Regarding current trading prices, DYN is priced at $17.24, while NUVL trades at $91.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas NUVL's P/E ratio is -15.07. In terms of profitability, DYN's ROE is -0.58%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, DYN is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check NUVL's competition here
DYN vs LEGN Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, LEGN has a market cap of 6.7B. Regarding current trading prices, DYN is priced at $17.24, while LEGN trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas LEGN's P/E ratio is -26.29. In terms of profitability, DYN's ROE is -0.58%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, DYN is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check LEGN's competition here
DYN vs RETA Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DYN is priced at $17.24, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas RETA's P/E ratio is -66.29. In terms of profitability, DYN's ROE is -0.58%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DYN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RETA's competition here
DYN vs IMVT Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, IMVT has a market cap of 6.3B. Regarding current trading prices, DYN is priced at $17.24, while IMVT trades at $30.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas IMVT's P/E ratio is -11.16. In terms of profitability, DYN's ROE is -0.58%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, DYN is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check IMVT's competition here
DYN vs CNTA Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, DYN is priced at $17.24, while CNTA trades at $39.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CNTA's P/E ratio is -22.42. In terms of profitability, DYN's ROE is -0.58%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, DYN is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CNTA's competition here
DYN vs PTGX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, PTGX has a market cap of 6B. Regarding current trading prices, DYN is priced at $17.24, while PTGX trades at $93.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas PTGX's P/E ratio is -51.56. In terms of profitability, DYN's ROE is -0.58%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, DYN is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check PTGX's competition here
DYN vs KYMR Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, KYMR has a market cap of 5.9B. Regarding current trading prices, DYN is priced at $17.24, while KYMR trades at $71.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas KYMR's P/E ratio is -19.91. In terms of profitability, DYN's ROE is -0.58%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, DYN is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check KYMR's competition here
DYN vs RYTM Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, DYN is priced at $17.24, while RYTM trades at $84.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas RYTM's P/E ratio is -26.95. In terms of profitability, DYN's ROE is -0.58%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, DYN is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RYTM's competition here
DYN vs PTCT Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, DYN is priced at $17.24, while PTCT trades at $68.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas PTCT's P/E ratio is -26.86. In terms of profitability, DYN's ROE is -0.58%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, DYN is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check PTCT's competition here
DYN vs CDTX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, DYN is priced at $17.24, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CDTX's P/E ratio is -19.77. In terms of profitability, DYN's ROE is -0.58%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, DYN is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CDTX's competition here
DYN vs TGTX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, TGTX has a market cap of 5.6B. Regarding current trading prices, DYN is priced at $17.24, while TGTX trades at $36.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas TGTX's P/E ratio is 12.81. In terms of profitability, DYN's ROE is -0.58%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, DYN is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TGTX's competition here
DYN vs COGT Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, COGT has a market cap of 5.6B. Regarding current trading prices, DYN is priced at $17.24, while COGT trades at $32.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas COGT's P/E ratio is -15.10. In terms of profitability, DYN's ROE is -0.58%, compared to COGT's ROE of -0.83%. Regarding short-term risk, DYN is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check COGT's competition here
DYN vs ABCM Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DYN is priced at $17.24, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DYN's ROE is -0.58%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DYN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ABCM's competition here
DYN vs ISEE Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DYN is priced at $17.24, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DYN's ROE is -0.58%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DYN is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ISEE's competition here
DYN vs PRAX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, PRAX has a market cap of 5.5B. Regarding current trading prices, DYN is priced at $17.24, while PRAX trades at $258.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas PRAX's P/E ratio is -19.26. In terms of profitability, DYN's ROE is -0.58%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, DYN is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check PRAX's competition here
DYN vs BLTE Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, BLTE has a market cap of 5.4B. Regarding current trading prices, DYN is priced at $17.24, while BLTE trades at $134.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas BLTE's P/E ratio is -52.91. In terms of profitability, DYN's ROE is -0.58%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, DYN is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check BLTE's competition here
DYN vs SRRK Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, SRRK has a market cap of 5.4B. Regarding current trading prices, DYN is priced at $17.24, while SRRK trades at $44.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas SRRK's P/E ratio is -12.95. In terms of profitability, DYN's ROE is -0.58%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, DYN is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check SRRK's competition here
DYN vs APLS Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, DYN is priced at $17.24, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas APLS's P/E ratio is 38.35. In terms of profitability, DYN's ROE is -0.58%, compared to APLS's ROE of +0.40%. Regarding short-term risk, DYN is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check APLS's competition here
DYN vs FBIOX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, FBIOX has a market cap of 5B. Regarding current trading prices, DYN is priced at $17.24, while FBIOX trades at $24.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas FBIOX's P/E ratio is N/A. In terms of profitability, DYN's ROE is -0.58%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, DYN is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check FBIOX's competition here
DYN vs CRSP Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, DYN is priced at $17.24, while CRSP trades at $52.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CRSP's P/E ratio is -8.43. In terms of profitability, DYN's ROE is -0.58%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, DYN is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CRSP's competition here
DYN vs LQDA Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, LQDA has a market cap of 4.9B. Regarding current trading prices, DYN is priced at $17.24, while LQDA trades at $55.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas LQDA's P/E ratio is 324.18. In terms of profitability, DYN's ROE is -0.58%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, DYN is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check LQDA's competition here
DYN vs CGON Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CGON has a market cap of 4.9B. Regarding current trading prices, DYN is priced at $17.24, while CGON trades at $55.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CGON's P/E ratio is -23.73. In terms of profitability, DYN's ROE is -0.58%, compared to CGON's ROE of -0.23%. Regarding short-term risk, DYN is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CGON's competition here
DYN vs APGE Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, APGE has a market cap of 4.9B. Regarding current trading prices, DYN is priced at $17.24, while APGE trades at $78.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas APGE's P/E ratio is -18.18. In terms of profitability, DYN's ROE is -0.58%, compared to APGE's ROE of -0.33%. Regarding short-term risk, DYN is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check APGE's competition here
DYN vs TERN Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, DYN is priced at $17.24, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas TERN's P/E ratio is -51.41. In terms of profitability, DYN's ROE is -0.58%, compared to TERN's ROE of -0.20%. Regarding short-term risk, DYN is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TERN's competition here
DYN vs ABVX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ABVX has a market cap of 4.8B. Regarding current trading prices, DYN is priced at $17.24, while ABVX trades at $72.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ABVX's P/E ratio is -13.53. In terms of profitability, DYN's ROE is -0.58%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, DYN is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check ABVX's competition here
DYN vs CAI Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, DYN is priced at $17.24, while CAI trades at $16.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CAI's P/E ratio is -5.99. In terms of profitability, DYN's ROE is -0.58%, compared to CAI's ROE of +0.06%. Regarding short-term risk, DYN is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CAI's competition here
DYN vs LGND Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, LGND has a market cap of 4.7B. Regarding current trading prices, DYN is priced at $17.24, while LGND trades at $232.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas LGND's P/E ratio is 30.31. In terms of profitability, DYN's ROE is -0.58%, compared to LGND's ROE of +0.16%. Regarding short-term risk, DYN is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check LGND's competition here
DYN vs MIRM Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, MIRM has a market cap of 4.6B. Regarding current trading prices, DYN is priced at $17.24, while MIRM trades at $92.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas MIRM's P/E ratio is -6.78. In terms of profitability, DYN's ROE is -0.58%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, DYN is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MIRM's competition here
DYN vs FOLD Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, DYN is priced at $17.24, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas FOLD's P/E ratio is -161.00. In terms of profitability, DYN's ROE is -0.58%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, DYN is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check FOLD's competition here
DYN vs AKRO Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, DYN is priced at $17.24, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas AKRO's P/E ratio is -14.57. In terms of profitability, DYN's ROE is -0.58%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, DYN is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check AKRO's competition here
DYN vs CELC Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, DYN is priced at $17.24, while CELC trades at $91.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CELC's P/E ratio is -23.44. In terms of profitability, DYN's ROE is -0.58%, compared to CELC's ROE of -2.45%. Regarding short-term risk, DYN is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check CELC's competition here
DYN vs ALPN Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DYN is priced at $17.24, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DYN's ROE is -0.58%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, DYN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ALPN's competition here
DYN vs OPT Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DYN is priced at $17.24, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas OPT's P/E ratio is -1.52. In terms of profitability, DYN's ROE is -0.58%, compared to OPT's ROE of +0.88%. Regarding short-term risk, DYN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check OPT's competition here
DYN vs ERAS Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, DYN is priced at $17.24, while ERAS trades at $13.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ERAS's P/E ratio is -14.49. In terms of profitability, DYN's ROE is -0.58%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, DYN is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ERAS's competition here
DYN vs SYRE Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, SYRE has a market cap of 4.2B. Regarding current trading prices, DYN is priced at $17.24, while SYRE trades at $69.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas SYRE's P/E ratio is -32.65. In terms of profitability, DYN's ROE is -0.58%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, DYN is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check SYRE's competition here
DYN vs XENE Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, XENE has a market cap of 4.1B. Regarding current trading prices, DYN is priced at $17.24, while XENE trades at $52.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas XENE's P/E ratio is -11.13. In terms of profitability, DYN's ROE is -0.58%, compared to XENE's ROE of -0.49%. Regarding short-term risk, DYN is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check XENE's competition here
DYN vs MRTX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DYN is priced at $17.24, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DYN's ROE is -0.58%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DYN is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MRTX's competition here
DYN vs MANE Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, MANE has a market cap of 4.1B. Regarding current trading prices, DYN is priced at $17.24, while MANE trades at $98.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas MANE's P/E ratio is -37.04. In terms of profitability, DYN's ROE is -0.58%, compared to MANE's ROE of -0.95%. Regarding short-term risk, DYN is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check MANE's competition here
DYN vs EWTX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, EWTX has a market cap of 4B. Regarding current trading prices, DYN is priced at $17.24, while EWTX trades at $37.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas EWTX's P/E ratio is -22.44. In terms of profitability, DYN's ROE is -0.58%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, DYN is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check EWTX's competition here
DYN vs TVTX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, TVTX has a market cap of 4B. Regarding current trading prices, DYN is priced at $17.24, while TVTX trades at $42.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas TVTX's P/E ratio is -85.92. In terms of profitability, DYN's ROE is -0.58%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, DYN is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TVTX's competition here
DYN vs CPRX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, DYN is priced at $17.24, while CPRX trades at $31.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CPRX's P/E ratio is 18.08. In terms of profitability, DYN's ROE is -0.58%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, DYN is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CPRX's competition here
DYN vs VCYT Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, VCYT has a market cap of 3.8B. Regarding current trading prices, DYN is priced at $17.24, while VCYT trades at $47.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas VCYT's P/E ratio is 44.26. In terms of profitability, DYN's ROE is -0.58%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, DYN is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check VCYT's competition here
DYN vs RYZB Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DYN is priced at $17.24, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DYN's ROE is -0.58%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DYN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check RYZB's competition here
DYN vs CBAY Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DYN is priced at $17.24, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DYN's ROE is -0.58%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DYN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CBAY's competition here
DYN vs NAMS Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, NAMS has a market cap of 3.7B. Regarding current trading prices, DYN is priced at $17.24, while NAMS trades at $31.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas NAMS's P/E ratio is -17.81. In terms of profitability, DYN's ROE is -0.58%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, DYN is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check NAMS's competition here
DYN vs ACAD Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, DYN is priced at $17.24, while ACAD trades at $20.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas ACAD's P/E ratio is 9.45. In terms of profitability, DYN's ROE is -0.58%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, DYN is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check ACAD's competition here
DYN vs SWTX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, DYN is priced at $17.24, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas SWTX's P/E ratio is -13.78. In terms of profitability, DYN's ROE is -0.58%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, DYN is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check SWTX's competition here
DYN vs KNSA Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, KNSA has a market cap of 3.5B. Regarding current trading prices, DYN is priced at $17.24, while KNSA trades at $46.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas KNSA's P/E ratio is 51.56. In terms of profitability, DYN's ROE is -0.58%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, DYN is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check KNSA's competition here
DYN vs CRNX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, CRNX has a market cap of 3.4B. Regarding current trading prices, DYN is priced at $17.24, while CRNX trades at $32.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas CRNX's P/E ratio is -6.35. In terms of profitability, DYN's ROE is -0.58%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, DYN is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check CRNX's competition here
DYN vs DNTH Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, DNTH has a market cap of 3.4B. Regarding current trading prices, DYN is priced at $17.24, while DNTH trades at $81.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas DNTH's P/E ratio is -19.28. In terms of profitability, DYN's ROE is -0.58%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, DYN is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for DYN.Check DNTH's competition here
DYN vs VKTX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, VKTX has a market cap of 3.4B. Regarding current trading prices, DYN is priced at $17.24, while VKTX trades at $29.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas VKTX's P/E ratio is -7.06. In terms of profitability, DYN's ROE is -0.58%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, DYN is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check VKTX's competition here
DYN vs TLX Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, TLX has a market cap of 3.1B. Regarding current trading prices, DYN is priced at $17.24, while TLX trades at $9.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas TLX's P/E ratio is -458.00. In terms of profitability, DYN's ROE is -0.58%, compared to TLX's ROE of -0.02%. Regarding short-term risk, DYN is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check TLX's competition here
DYN vs DNLI Comparison June 2026
DYN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DYN stands at 2.9B. In comparison, DNLI has a market cap of 3.1B. Regarding current trading prices, DYN is priced at $17.24, while DNLI trades at $19.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DYN currently has a P/E ratio of -5.47, whereas DNLI's P/E ratio is -6.72. In terms of profitability, DYN's ROE is -0.58%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, DYN is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for DYN.Check DNLI's competition here